Omar Nadeem

2.1k total citations
79 papers, 468 citations indexed

About

Omar Nadeem is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Omar Nadeem has authored 79 papers receiving a total of 468 indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Hematology, 43 papers in Oncology and 29 papers in Molecular Biology. Recurrent topics in Omar Nadeem's work include Multiple Myeloma Research and Treatments (52 papers), Protein Degradation and Inhibitors (20 papers) and CAR-T cell therapy research (15 papers). Omar Nadeem is often cited by papers focused on Multiple Myeloma Research and Treatments (52 papers), Protein Degradation and Inhibitors (20 papers) and CAR-T cell therapy research (15 papers). Omar Nadeem collaborates with scholars based in United States, Spain and Italy. Omar Nadeem's co-authors include Paul G. Richardson, Kenneth C. Anderson, Jacob P. Laubach, Jiang Gui, Noopur Raje, Deborah L. Ornstein, Adam S. Sperling, Clifton C. Mo, Elizabeth O’Donnell and Leona Holmberg and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Omar Nadeem

70 papers receiving 462 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Omar Nadeem United States 13 263 260 229 58 50 79 468
Danai Dima United States 12 180 0.7× 233 0.9× 170 0.7× 40 0.7× 30 0.6× 69 409
Jagoda Jasielec United States 13 390 1.5× 252 1.0× 339 1.5× 44 0.8× 16 0.3× 40 553
Shakira J. Grant United States 9 151 0.6× 192 0.7× 87 0.4× 38 0.7× 30 0.6× 39 373
Clifton C. Mo United States 11 242 0.9× 177 0.7× 216 0.9× 69 1.2× 18 0.4× 44 489
Keqin Qi United States 10 164 0.6× 180 0.7× 124 0.5× 47 0.8× 43 0.9× 33 348
Kejal Parikh United States 10 446 1.7× 298 1.1× 280 1.2× 113 1.9× 38 0.8× 40 634
H. Goldschmidt Germany 11 265 1.0× 228 0.9× 147 0.6× 60 1.0× 18 0.4× 34 447
Lisa Koch United States 11 98 0.4× 170 0.7× 111 0.5× 23 0.4× 32 0.6× 22 533
Minako Iida Japan 7 290 1.1× 102 0.4× 80 0.3× 78 1.3× 17 0.3× 13 436
Jason H. Mendler United States 13 298 1.1× 198 0.8× 322 1.4× 71 1.2× 11 0.2× 53 787

Countries citing papers authored by Omar Nadeem

Since Specialization
Citations

This map shows the geographic impact of Omar Nadeem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Omar Nadeem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Omar Nadeem more than expected).

Fields of papers citing papers by Omar Nadeem

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Omar Nadeem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Omar Nadeem. The network helps show where Omar Nadeem may publish in the future.

Co-authorship network of co-authors of Omar Nadeem

This figure shows the co-authorship network connecting the top 25 collaborators of Omar Nadeem. A scholar is included among the top collaborators of Omar Nadeem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Omar Nadeem. Omar Nadeem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Little, Jessica S, Andrew J. Yee, Omar Nadeem, et al.. (2025). Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy. Blood Advances. 9(16). 4190–4194. 1 indexed citations
2.
O’Donnell, Elizabeth, Jennifer Carroll, Jennifer C. Perry, et al.. (2025). Distress and symptom burden in patients with monoclonal gammopathy of undetermined significance and smoldering myeloma. Blood Advances. 9(8). 1984–1987.
3.
Mo, Clifton C., et al.. (2025). SOHO State of the Art Updates and Next Questions | Late/Deferred ASCT in Myeloma. Clinical Lymphoma Myeloma & Leukemia. 25(11). 775–787.
4.
Pawlyn, Charlotte, Fredrik Schjesvold, David A. Cairns, et al.. (2024). Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. Blood Cancer Journal. 14(1). 134–134. 4 indexed citations
5.
Ackerman, Benjamin, Ryan W. Gan, Craig S. Meyer, et al.. (2024). Measurement error and bias in real-world oncology endpoints when constructing external control arms. SHILAP Revista de lepidopterología. 4. 1423493–1423493. 1 indexed citations
6.
Mo, Clifton C., et al.. (2024). Mezigdomide—A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma. Cancers. 16(6). 1166–1166. 8 indexed citations
7.
8.
O’Donnell, Elizabeth, Clifton C. Mo, Andrew J. Yee, et al.. (2024). Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial. The Lancet Haematology. 11(6). e415–e424. 8 indexed citations
9.
O’Donnell, Elizabeth, Clifton C. Mo, Andrew J. Yee, et al.. (2023). A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial). Blood. 142(Supplement 1). 4671–4671. 2 indexed citations
10.
Mo, Clifton C., Andrew J. Yee, Shonali Midha, et al.. (2023). Selinexor: Targeting a novel pathway in multiple myeloma. SHILAP Revista de lepidopterología. 4(3). 792–810. 17 indexed citations
11.
Little, Jessica S, Joseph Hong, Omar Nadeem, et al.. (2023). Respiratory infections predominate after day 100 following B-cell maturation antigen–directed CAR T-cell therapy. Blood Advances. 7(18). 5485–5495. 24 indexed citations
12.
Lee, David Jungpa, Elizabeth O’Donnell, Noopur Raje, et al.. (2023). Design and Rationale of Prolonged Nightly Fasting for Multiple Myeloma Prevention (PROFAST): Protocol for a Randomized Controlled Pilot Trial. JMIR Research Protocols. 13. e51368–e51368. 2 indexed citations
13.
Landgren, Ola & Omar Nadeem. (2023). Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast. Advances in Therapy. 40(8). 3291–3303. 9 indexed citations
14.
Midha, Shonali, Omar Nadeem, & Umut Selamet. (2022). Updates in Plasma Cell Dyscrasias and Related Monoclonal Immunoglobulin-Mediated Renal Disease. Seminars in Nephrology. 42(6). 151352–151352. 1 indexed citations
15.
Tuazon, Sherilyn A., Leona Holmberg, Omar Nadeem, & Paul G. Richardson. (2021). A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer Journal. 11(2). 23–23. 32 indexed citations
16.
Nadeem, Omar, Y-T Tai, & KC Anderson. (2020). Immunotherapeutic and Targeted Approaches in Multiple Myeloma. SHILAP Revista de lepidopterología.
17.
Vogl, Dan T., Jonathan L. Kaufman, Omar Nadeem, et al.. (2020). TAK-573, an Anti-CD38/Attenuated Ifnα Fusion Protein, Has Clinical Activity and Modulates the Ifnα Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 136(Supplement 1). 37–38. 17 indexed citations
18.
Nadeem, Omar, Yu‐Tzu Tai, & Kenneth C. Anderson. (2020). <p>Immunotherapeutic and Targeted Approaches in Multiple Myeloma</p>. ImmunoTargets and Therapy. Volume 9. 201–215. 16 indexed citations
19.
Nadeem, Omar, Diana O. Treaba, James N. Butera, & Jorge J. Castillo. (2014). B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma: A Review of Reported Cases. 1(1). 1–7. 2 indexed citations
20.
Castillo, Jorge J. & Omar Nadeem. (2013). Improving the accuracy in prognosis for Burkitt lymphoma patients. Expert Review of Anticancer Therapy. 14(2). 125–127. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Danai Dima Breakdown of academic impact, for papers by Jagoda Jasielec Breakdown of academic impact, for papers by Shakira J. Grant Breakdown of academic impact, for papers by Clifton C. Mo Breakdown of academic impact, for papers by Keqin Qi Breakdown of academic impact, for papers by Kejal Parikh Breakdown of academic impact, for papers by H. Goldschmidt Breakdown of academic impact, for papers by Lisa Koch Breakdown of academic impact, for papers by Minako Iida Breakdown of academic impact, for papers by Jason H. Mendler
Rankless by CCL
2026